Re: predicting which Stage IVs will respond best to lapatinib+capecitabine
I hope the doctors that are treating HER+ patients read this. I do not know how many look at HER2, HER3, and 95HER2 marker testing. I will see whether they did this with Nina as the Xeloda/Tykerb mix stabilized the disease in the brain. Nina has never had disease seen elsewhere, although blood cells and markers in the blood showed that there was a potential for that to occur.
As Always, thank you Lani for your work in this area.
|